J&J's Gamma First PMA Submission For Vascular Brachytherapy System
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's premarket approval application for the Gamma brachytherapy system for treatment of coronary artery disease has been granted expedited review by FDA and potentially could be approved by year-end or early 2000, the company indicated following its announcement July 14 of the PMA filing.